Prime Medicine Began Clinical Trial for Wilson Disease
The company has dosed the first patient in a trial for a gene-editing therapy targeting a rare genetic disorder.
Updated on Oct. 5, 2026 in Biotech
Live Poll
Should the federal government increase support for research into rare genetic diseases?
Prime Medicine has officially dosed the first patient in a Phase 1/2 clinical trial for PM577a, an investigational treatment for Wilson disease. The U.S. FDA has also granted Rare Pediatric Disease designation to the therapy.
Why it matters
Wilson disease is a genetic condition caused by faulty copper transport, and this trial marks a step toward using Prime Editing technology to correct the underlying H1069Q mutation in the ATP7B gene at its source.
The clinical trial utilizes an investigational in vivo Prime Editor to target the H1069Q mutation. The therapy is administered as a single intravenous infusion to participants.
The players
Prime Medicine
This biotechnology company is based in Cambridge, Massachusetts, and specializes in gene-editing platforms.
U.S. Food and Drug Administration
This federal agency is responsible for protecting public health by regulating medical products and granting special designations.
The details
This open-label, first-in-human study focuses on adults and adolescents who carry the H1069Q mutation. By utilizing Prime Editing, researchers aim to address the root cause of hepatic copper transport failure in patients.
Timeline
October 5, 2026: Prime Medicine announced the dosing of the first patient.
2027: The company expects to release initial clinical trial data.
The Tech Race
This trial follows the regulatory path established by the FDA Rare Pediatric Disease designation program, which incentivizes development for rare childhood conditions. It represents a shift toward permanent genetic correction for metabolic diseases rather than traditional symptom management.
For patients and families affected by Wilson disease, this trial represents a potential move toward a curative one-time treatment. Participants and stakeholders will monitor for trial progress and clinical safety reports as the development timeline advances.
The takeaway
The initiation of this trial signals a significant advancement in applying Prime Editing to inherited hepatic conditions. Patients should stay informed on upcoming milestones as researchers gather data on this potential genetic correction strategy.
What happens next
The company expects to release initial clinical data from the ongoing trial in 2027.
Further reading
Learn more about the latest innovations in genetic therapy in the Biotech section.
More information
View the full clinical trial information page for details on the study design.
Live Poll
Should the federal government increase support for research into rare genetic diseases?
